Bill Overview
Title: Agility in Manufacturing Preparedness Act
Description: This bill requires the Department of Health and Human Services (HHS) to seek to contract with the National Institute for Innovation in Manufacturing Biopharmaceuticals to assess and make recommendations concerning U.S. capabilities for biopharmaceutical manufacturing and related matters. HHS must coordinate with the Biomedical Advanced Research and Development Authority on this contract.
Sponsors: Sen. Rubio, Marco [R-FL]
Target Audience
Population: Individuals employed in biopharmaceutical manufacturing and related sectors
Estimated Size: 250000
- The bill focuses on biopharmaceutical manufacturing, which is a specialized industry.
- The workforce employed in the biopharmaceutical manufacturing sector includes people specialized in pharmaceuticals, biotechnology, and related technical disciplines.
- Broader impacts might extend to those who indirectly support this industry such as suppliers and logistics companies.
- The act is likely to affect policy and infrastructure related to health preparedness and capabilities in the USA.
Reasoning
- The policy budget is limited, focusing on strategic planning and recommendations rather than immediate direct allocations to individuals or companies.
- Since the main focus is on preparedness and manufacturing capacity, most direct impacts are centered around biopharmaceutical and biotechnology sectors, impacting organizations and individuals within these fields.
- Although the reach is potentially large given the strategic importance of biopharmaceuticals to health security, immediate and direct effects on individual well-being may be subtle and long-term.
- Individuals and businesses currently engaged in related manufacturing or those dealing with supply chains may see some changes in strategic direction or funding priorities.
- Although 250,000 individuals are targeted, many others might only be tangentially affected if related policies or contracts shift due to this Act.
- Most of the perceived benefits and changes will be indirect and rely on further applications and policies following this initial assessment and recommendation phase.
- The Cantril wellbeing scale provides an impression of perceived happiness and satisfactory state, but in this case, the biggest shifts may be long-term depending on how recommendations are implemented.
Simulated Interviews
Biopharmaceutical Manufacturer (Boston, MA)
Age: 45 | Gender: male
Wellbeing Before Policy: 7
Duration of Impact: 10.0 years
Commonness: 4/20
Statement of Opinion:
- The policy might enhance our competitive edge in global markets.
- I expect investments to follow in the future leading to job stability.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 7 | 7 |
| Year 2 | 7 | 6 |
| Year 3 | 7 | 6 |
| Year 5 | 8 | 6 |
| Year 10 | 8 | 5 |
| Year 20 | 8 | 5 |
Biotechnology Researcher (San Diego, CA)
Age: 30 | Gender: female
Wellbeing Before Policy: 6
Duration of Impact: 5.0 years
Commonness: 5/20
Statement of Opinion:
- It could steer more funding towards R&D that we can benefit from.
- Initial changes might not be visible but future growth potential is exciting.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 6 | 6 |
| Year 2 | 6 | 6 |
| Year 3 | 7 | 6 |
| Year 5 | 7 | 6 |
| Year 10 | 8 | 6 |
| Year 20 | 8 | 6 |
Logistics Coordinator (Raleigh, NC)
Age: 50 | Gender: female
Wellbeing Before Policy: 5
Duration of Impact: 7.0 years
Commonness: 7/20
Statement of Opinion:
- Potential for increased logistic demands and technology upgrades.
- I am cautiously optimistic about the strategic benefits.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 5 | 5 |
| Year 2 | 5 | 5 |
| Year 3 | 6 | 5 |
| Year 5 | 6 | 5 |
| Year 10 | 6 | 5 |
| Year 20 | 6 | 5 |
Software Engineer (Austin, TX)
Age: 38 | Gender: male
Wellbeing Before Policy: 8
Duration of Impact: 4.0 years
Commonness: 6/20
Statement of Opinion:
- Not sure about immediate changes to my role but could lead to more projects.
- Long-term investments in infrastructure can improve work satisfaction.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 8 | 8 |
| Year 2 | 8 | 8 |
| Year 3 | 9 | 8 |
| Year 5 | 9 | 8 |
| Year 10 | 9 | 8 |
| Year 20 | 9 | 8 |
Healthcare Policy Analyst (Miami, FL)
Age: 29 | Gender: female
Wellbeing Before Policy: 7
Duration of Impact: 0.0 years
Commonness: 8/20
Statement of Opinion:
- This policy might not change the immediate landscape but could inform future regulations.
- A step forward in considering our infrastructure capabilities.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 7 | 7 |
| Year 2 | 7 | 7 |
| Year 3 | 7 | 7 |
| Year 5 | 7 | 7 |
| Year 10 | 7 | 7 |
| Year 20 | 7 | 7 |
Factory Worker (Detroit, MI)
Age: 55 | Gender: male
Wellbeing Before Policy: 6
Duration of Impact: 3.0 years
Commonness: 10/20
Statement of Opinion:
- I doubt it'll change things much here unless projects expand.
- Hoping for more resources or projects but not counting on it soon.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 6 | 6 |
| Year 2 | 6 | 6 |
| Year 3 | 6 | 6 |
| Year 5 | 7 | 6 |
| Year 10 | 7 | 6 |
| Year 20 | 7 | 6 |
Supply Chain Analyst (Newark, NJ)
Age: 42 | Gender: female
Wellbeing Before Policy: 7
Duration of Impact: 8.0 years
Commonness: 5/20
Statement of Opinion:
- Strategic plans like this could spur investments in supply chain tech.
- Encouraged by a framework that acknowledges the need for manufacturing capabilities.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 7 | 7 |
| Year 2 | 7 | 6 |
| Year 3 | 8 | 6 |
| Year 5 | 8 | 6 |
| Year 10 | 9 | 6 |
| Year 20 | 9 | 6 |
Biotech Startup Founder (Seattle, WA)
Age: 27 | Gender: male
Wellbeing Before Policy: 8
Duration of Impact: 5.0 years
Commonness: 3/20
Statement of Opinion:
- Optimistic for potential grant redirections or consideration of innovative startups.
- This is mostly a starting point but aligns with growth strategies for startups.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 8 | 8 |
| Year 2 | 8 | 8 |
| Year 3 | 9 | 8 |
| Year 5 | 9 | 8 |
| Year 10 | 9 | 8 |
| Year 20 | 9 | 8 |
Retired (Philadelphia, PA)
Age: 60 | Gender: female
Wellbeing Before Policy: 7
Duration of Impact: 0.0 years
Commonness: 4/20
Statement of Opinion:
- Hopeful that this policy signals a commitment to expanding bioscientific capabilities.
- Feels positive about mentoring opportunities for the younger workforce.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 7 | 7 |
| Year 2 | 7 | 7 |
| Year 3 | 7 | 7 |
| Year 5 | 7 | 7 |
| Year 10 | 7 | 7 |
| Year 20 | 7 | 7 |
Regulatory Affairs Specialist (Chicago, IL)
Age: 36 | Gender: male
Wellbeing Before Policy: 6
Duration of Impact: 6.0 years
Commonness: 7/20
Statement of Opinion:
- Legislative policies like this one are crucial indicators of where we are headed.
- Expect limited immediate impact on day-to-day work until more data is available.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 6 | 6 |
| Year 2 | 6 | 6 |
| Year 3 | 6 | 6 |
| Year 5 | 7 | 6 |
| Year 10 | 7 | 6 |
| Year 20 | 7 | 6 |
Cost Estimates
Year 1: $5000000 (Low: $4000000, High: $6000000)
Year 2: $5000000 (Low: $4000000, High: $6000000)
Year 3: $5000000 (Low: $4000000, High: $6000000)
Year 5: $5000000 (Low: $4000000, High: $6000000)
Year 10: $0 (Low: $0, High: $0)
Year 100: $0 (Low: $0, High: $0)
Key Considerations
- The rapidly evolving nature of biopharmaceutical manufacturing technologies requires ongoing assessment and adaptability.
- Enhanced capabilities could decrease dependence on international supply chains, which is a strategic advantage for national security and public health.
- Close coordination between government agencies and the private sector is essential to effectively implement the recommendations from the assessment.